Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy

This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent.

Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment.

A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95%CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95%CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95%CI=4.7-33.0).

RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule.

Anticancer research. 2017 Jul [Epub]

Beatrice Detti, Rolando M D'Angelillo, Gianluca Ingrosso, Emanuela Olmetto, Giulio Francolini, Luca Triggiani, Alessio Bruni, Simona Borghesi, Simona Fondelli, Tommaso Carfagno, Roberto Santini, Riccardo Santoni, Luca E Trodella, Lorenzo Livi

Department of Radiation Oncology, AOU Careggi, Florence, Italy., Department of Radiation Oncology, University Campus Bio-Medico di Roma, Rome, Italy., Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, Tor Vergata General Hospital, Rome, Italy., Department of Radiation Oncology, AOU Careggi, Florence, Italy ., Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy., Department of Radiation Oncology, AOU Policlinico di Modena, Modena, Italy., Department of Radiation Oncology, Ospedale San Donato Arezzo, Arezzo, Italy., Department of Radiation Oncology, Azienda USL Toscana-Centro, Ospedale S. Maria Annunziata, Florence, Italy., Department of Radiation Oncology, Azienda Ospedaliera Universitaria Senese, Siena, Italy., Department of Radiation Oncology, Ospedale San Jacopo Pistoia, Pistoia, Italy.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe